Chronic Granulomatous Disease
GPTKB entity
Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Genetics
|
| gptkbp:affects |
immune system
|
| gptkbp:associated_with |
patient education
support groups antimicrobial resistance financial burden nutritional deficiencies genetic counseling chronic pain management increased hospitalizations chronic inflammation increased mortality risk chronic fatigue healthcare access issues surgical interventions psychosocial issues psychological support needs long-term follow-up multidisciplinary care approach poor quality of life emergency care plans delayed wound healing social support systems catalase-positive organisms |
| gptkbp:caused_by |
defects in NADPH oxidase
|
| gptkbp:complication |
gptkb:Oncology
autoimmune disorders abscess formation granulomatous inflammation |
| gptkbp:diagnosis |
blood tests
dihydrorhodamine test nitroblue tetrazolium test |
| gptkbp:first_described_by |
1950s
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chronic Granulomatous Disease
|
| gptkbp:inherits_from |
autosomal recessive
X-linked recessive |
| gptkbp:management |
regular monitoring
vaccinations avoidance of certain pathogens |
| gptkbp:prevalence |
rare disorder
|
| gptkbp:promoter |
gptkb:CYBB
gptkb:CYBA gptkb:NCF1 gptkb:NCF4 NCF2 |
| gptkbp:research |
gptkb:gene_therapy
clinical trials new antibiotics immunomodulatory therapies |
| gptkbp:risk_factor |
family history
ethnicity |
| gptkbp:symptoms |
granuloma formation
recurrent bacterial infections |
| gptkbp:treatment |
gptkb:interferon-gamma
antibiotics bone marrow transplant |
| gptkbp:bfsParent |
gptkb:CYBA
|
| gptkbp:bfsLayer |
6
|